A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors Meeting Abstract
| Authors: | Burris, H. A.; Gordon, M. S.; Hellmann, M. D.; LoRusso, P.; Emens, L. A.; Hodi, F. S.; Lieu, C. H.; Infante, J. R.; Tsai, F. Y. C.; Eder, J. P.; Cleary, J. M.; Jelovac, D.; Tsuhako, A. L.; Mueller, L.; Lin, R.; Morrissey, K.; Mahrus, S.; Morley, R.; Pirzkall, A.; Davis, S. L. |
| Abstract Title: | A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 7s |
| Language: | English |
| ACCESSION: | WOS:000411895700014 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.105 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 105 -- Source: Wos |
